ATE293164T1 - Modifizierte chimärische polypeptide mit verbesserten pharmakokynetischen eigenschaften - Google Patents

Modifizierte chimärische polypeptide mit verbesserten pharmakokynetischen eigenschaften

Info

Publication number
ATE293164T1
ATE293164T1 AT00932721T AT00932721T ATE293164T1 AT E293164 T1 ATE293164 T1 AT E293164T1 AT 00932721 T AT00932721 T AT 00932721T AT 00932721 T AT00932721 T AT 00932721T AT E293164 T1 ATE293164 T1 AT E293164T1
Authority
AT
Austria
Prior art keywords
improved
chimeric polypeptides
pharmacocynetic
properties
modified chimeric
Prior art date
Application number
AT00932721T
Other languages
German (de)
English (en)
Inventor
Nicholas J Papadopoulos
Samuel Davis
George D Yancopoulos
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22480568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE293164(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of ATE293164T1 publication Critical patent/ATE293164T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
AT00932721T 1999-06-08 2000-05-23 Modifizierte chimärische polypeptide mit verbesserten pharmakokynetischen eigenschaften ATE293164T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13813399P 1999-06-08 1999-06-08
PCT/US2000/014142 WO2000075319A1 (en) 1999-06-08 2000-05-23 Modified chimeric polypeptides with improved pharmacokinetic properties

Publications (1)

Publication Number Publication Date
ATE293164T1 true ATE293164T1 (de) 2005-04-15

Family

ID=22480568

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00932721T ATE293164T1 (de) 1999-06-08 2000-05-23 Modifizierte chimärische polypeptide mit verbesserten pharmakokynetischen eigenschaften
AT05001328T ATE417928T1 (de) 1999-06-08 2000-05-23 Vegf-rezeptorchimären zur behandlung von augenkrankheiten, welche durch vaskuläre permeabilität charakterisiert sind.

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT05001328T ATE417928T1 (de) 1999-06-08 2000-05-23 Vegf-rezeptorchimären zur behandlung von augenkrankheiten, welche durch vaskuläre permeabilität charakterisiert sind.

Country Status (32)

Country Link
EP (2) EP1544299B1 (enExample)
JP (2) JP4723140B2 (enExample)
KR (1) KR100659477B1 (enExample)
CN (3) CN101433715B (enExample)
AT (2) ATE293164T1 (enExample)
AU (2) AU779303B2 (enExample)
BE (1) BE2013C029I2 (enExample)
BR (2) BRPI0011407B8 (enExample)
CA (1) CA2376379C (enExample)
CY (2) CY1108883T1 (enExample)
CZ (2) CZ303656B6 (enExample)
DE (2) DE60041159D1 (enExample)
DK (2) DK1183353T3 (enExample)
ES (2) ES2237429T3 (enExample)
FR (1) FR13C0028I2 (enExample)
HR (1) HRP20010908B1 (enExample)
HU (3) HU230159B1 (enExample)
IL (3) IL146890A0 (enExample)
LT (1) LTC1183353I2 (enExample)
LU (1) LU92195I2 (enExample)
ME (2) ME00024B (enExample)
MX (1) MXPA01012630A (enExample)
NO (4) NO330775B1 (enExample)
NZ (1) NZ515913A (enExample)
PL (1) PL208247B1 (enExample)
PT (2) PT1183353E (enExample)
RS (1) RS50073B (enExample)
RU (1) RU2265661C2 (enExample)
SK (1) SK287332B6 (enExample)
UA (1) UA74146C2 (enExample)
WO (1) WO2000075319A1 (enExample)
ZA (1) ZA200110068B (enExample)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710174B2 (en) 2001-09-13 2004-03-23 Isis Pharmaceuticals, Inc. Antisense inhibition of vascular endothelial growth factor receptor-1 expression
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US7087411B2 (en) * 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
US7396664B2 (en) 1999-06-08 2008-07-08 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
US7070959B1 (en) 1999-06-08 2006-07-04 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
JP4669984B2 (ja) 2001-01-19 2011-04-13 ベジェニクス リミテッド 腫瘍画像化のターゲットとしてのＦ１ｔ４（ＶＥＧＦＲ−３）および抗腫瘍療法
US6734017B2 (en) 2001-09-28 2004-05-11 Isis Pharmaceuticals, Inc. Antisense modulation of vascular endothelial growth factor receptor-2 expression
EP1575548B1 (en) 2002-05-04 2011-03-09 Acorda Therapeutics, Inc. Compositions and methods for promoting neuronal outgrowth
JP4730909B2 (ja) * 2003-03-28 2011-07-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｖｅｇｆ媒介性活性を遮断することにより糖尿病を処置する方法
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
MX351062B (es) * 2003-05-16 2017-09-29 Acorda Therapeutics Inc Proteinas de fusion para el tratamiento del snc.
EP3211084B1 (en) 2003-05-16 2019-03-27 Acorda Therapeutics, Inc. Proteoglycan degrading mutants for treatment of cns
AU2004242586C1 (en) * 2003-05-28 2011-02-24 Regeneron Pharmaceuticals, Inc. Method of treating corneal transplant rejection by using VEGF antagonists
US7186699B2 (en) 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
CA2519875C (en) * 2003-06-06 2014-01-14 Regeneron Pharmaceuticals, Inc. Method of tumor regression with vegf inhibitors
US7399612B2 (en) 2003-06-30 2008-07-15 Regeneron Pharmaceuticals, Inc. VEGF-binding fusion proteins and nucleic acids encoding the same
AR046510A1 (es) * 2003-07-25 2005-12-14 Regeneron Pharma Composicion de un antagonista de vegf y un agente anti-proliferativo
JP2007501239A (ja) * 2003-08-06 2007-01-25 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 放射線治療と組み合わせたｖｅｇｆアンタゴニストの使用
AU2005244933B2 (en) 2004-05-18 2011-08-04 Acorda Therapeutics, Inc. Methods of purifying chondroitinase and stable formulations thereof
ES2381014T3 (es) * 2004-06-08 2012-05-22 Chengdu Kanghong Biotechnologies Co., Ltd. Proteína quimérica inhibidora de la angiogénesis y el uso
EP2583685A1 (en) 2004-06-10 2013-04-24 Regeneron Pharmaceuticals, Inc. Method of administering and using VEGF inhibitors for the treatment of human cancer
EP1755645A2 (en) * 2004-06-18 2007-02-28 Regeneron Pharmaceuticals, Inc. Vegf inhibitors for the treatment of malignant pleural effusion
CN1997386B (zh) * 2004-07-30 2012-05-30 瑞泽恩制药公司 通过阻断vegf介导的活性来治疗i型糖尿病的方法
CN101094688B (zh) * 2004-09-13 2013-05-01 建新公司 多聚构建体
FR2878749B1 (fr) * 2004-12-03 2007-12-21 Aventis Pharma Sa Combinaisons antitumorales contenant en agent inhibiteur de vegt et du 5fu ou un de ses derives
EP1877438A2 (en) 2005-02-02 2008-01-16 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a vegf inhibitor
CA3142945A1 (en) 2005-03-25 2006-10-05 Regeneron Pharmaceuticals, Inc. Histidine-buffered formulations of vegf antagonist
JP5189985B2 (ja) 2005-09-26 2013-04-24 アコーダ セラピューティクス、インク． コンドロイチナーゼａｂｃｉ変異体を用いた組成物およびその使用方法
PL1962895T3 (pl) † 2005-12-16 2013-06-28 Regeneron Pharma Terapeutyczne zastosowanie antagonisty dii4 oraz inhibitora vegf do inhibicji wzrostu nowotworów
FR2895258B1 (fr) 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
US8216575B2 (en) 2006-03-31 2012-07-10 Chengdu Kanghong Biotechnologies Co., Ltd. Inhibition of neovascularization with a soluble chimeric protein comprising VEGF FLT-1 and KDR domains
CN100502945C (zh) * 2006-03-31 2009-06-24 成都康弘生物科技有限公司 Vegf受体融合蛋白在治疗眼睛疾病中的应用
CA2654510C (en) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
HRP20160082T1 (hr) 2006-09-29 2016-02-26 Oncomed Pharmaceuticals, Inc. Sastavi i postupci za dijagnosticiranje i lijeäśenje raka
AU2007307736C1 (en) 2006-10-10 2014-04-10 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase ABCI mutants
FR2918279B1 (fr) * 2007-07-05 2010-10-22 Aventis Pharma Sa Combinaisons antitumorales contenant un agent inhibiteur de vegf et de l'irinotecan
CN101575379B (zh) * 2008-05-09 2012-05-30 上海抗体药物国家工程研究中心有限公司 可溶性vegfr双功能融合受体、其制备方法及用途
NZ592591A (en) 2008-11-03 2012-04-27 Molecular Partners Ag Binding proteins comprising ankyrin repeast domains that inhibit the vegf-a receptor interaction
CN101838329A (zh) * 2009-03-18 2010-09-22 嘉和生物药业有限公司 抗血管新生融合蛋白
EP3485908B1 (en) 2009-10-16 2021-08-18 Mereo BioPharma 5, Inc. Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
TWI510246B (zh) 2010-04-30 2015-12-01 Molecular Partners Ag 抑制ｖｅｇｆ－ａ受體交互作用的經修飾結合性蛋白質
PT2601214T (pt) 2010-08-06 2017-12-20 Genzyme Corp Composições de antagonistas de vegf e utilizações destes
US20140080153A1 (en) * 2011-01-07 2014-03-20 Chugai Seiyaku Kabushiki Kaisha Method for improving physical properties of antibody
KR20180023015A (ko) 2011-01-13 2018-03-06 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
JO3283B1 (ar) 2011-04-26 2018-09-16 Sanofi Sa تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI)
KR101397088B1 (ko) 2011-06-10 2014-05-19 강원대학교산학협력단 암세포 증식 억제와 혈관신생 억제를 위한 융합 단백질 및 이를 포함한 항암 조성물
JO3370B1 (ar) * 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
BR112014013205A2 (pt) 2011-12-01 2020-10-27 Protevobio, Inc. proteína de fusão, seu uso e seu método de produção, composição farmacêutica, ácido nucleico, e kit
CN103304668B (zh) * 2012-03-12 2015-10-28 江苏健德生物药业有限公司 Ultra-VEGF-trap免疫融合蛋白、其制备方法及其应用
PT2846836T (pt) 2012-05-07 2019-10-29 Allergan Inc Método de tratamento de dmi em doentes refratários à terapia anti-vegf
WO2014006113A1 (en) 2012-07-03 2014-01-09 Sanofi Method of treating cancer by effective amounts of aflibercept
TW201438736A (zh) 2012-11-14 2014-10-16 Regeneron Pharma 以ｄｌｌ４拮抗劑治療卵巢癌之方法
MY170528A (en) 2013-02-18 2019-08-09 Vegenics Pty Ltd Vegfr-3 ligand binding molecules and uses thereof
AR095196A1 (es) * 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
CN104193828B (zh) * 2013-09-12 2017-04-05 北京韩美药品有限公司 同时阻断her2和vegfr信号通路的重组融合蛋白
EP3628324A1 (en) 2013-11-05 2020-04-01 Allergan, Inc. Method of treating conditions of the eye with an anti-vegf darpin
WO2015173260A1 (en) 2014-05-12 2015-11-19 Formycon Ag Pre-filled plastic syringe containing a vegf antagonist
RS58957B1 (sr) 2014-07-18 2019-08-30 Sanofi Sa Postupak za predviđanje ishoda tretmana sa afliberceptom kod pacijenta za kog se sumnja da boluje od raka
JP2016036322A (ja) * 2014-08-11 2016-03-22 日本化薬株式会社 血管新生因子と結合するキメラタンパク質
CN106999511A (zh) 2014-12-11 2017-08-01 拜耳医药保健有限责任公司 具有小的活动性脉络膜新生血管病变的年龄相关性黄斑变性的治疗
GB201503453D0 (en) 2015-03-01 2015-04-15 Jain Arjun Endothelin-1"sponge"
TW202440903A (zh) 2015-08-04 2024-10-16 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法（一）
WO2017046140A1 (en) 2015-09-18 2017-03-23 Bayer Pharma Aktiengesellschaft Treatment regimens for dr and rvo in dependence of the extent of retinal ischemia
WO2017065559A1 (ko) 2015-10-15 2017-04-20 (주)알테오젠 Igg fc 도메인을 가지는 융합 단백질의 생산방법
KR101936049B1 (ko) * 2015-10-15 2019-01-08 (주)알테오젠 IgG Fc 도메인을 가지는 융합 단백질의 생산방법
US20180326126A1 (en) 2015-11-18 2018-11-15 Formycon Ag Pre-filled plastic syringe containing a vegf antagonist
CN108883172A (zh) 2015-11-18 2018-11-23 福迈康股份公司 包含vegf拮抗剂的液体配制品的预填充药物包装
KR102854749B1 (ko) 2015-11-18 2025-09-04 에스아이오2 메디컬 프로덕츠, 엘엘씨 안과 제제용 제약 패키지
CN108697792A (zh) * 2015-11-19 2018-10-23 珠海泰瑞尚生物医药科技有限公司 用于结合vegf的方法和组合物
KR20210157427A (ko) 2015-12-03 2021-12-28 리제너론 파마슈티칼스 인코포레이티드 항-vegf로 치료된 연령-관련 황반 변성을 앓고 있는 환자에서의 임상 결과와 유전적 변이체를 연관시키는 방법
EP3407868A1 (en) 2016-01-26 2018-12-05 Formycon AG Liquid formulation of a vegf antagonist
WO2018070390A1 (ja) 2016-10-12 2018-04-19 第一三共株式会社 抗ｒｏｂｏ４抗体と他剤を含む組成物
CN109937034B (zh) 2016-11-21 2022-09-16 济世-伊沃泰克生物制品有限公司 阿柏西普制剂及其用途
WO2018215580A1 (en) 2017-05-24 2018-11-29 Formycon Ag Method for sterilizing prefilled plastic syringes containing a vegf antagonist
WO2018217995A1 (en) 2017-05-24 2018-11-29 Formycon Ag Sterilizable pre-filled pharmaceutical packages comprising a liquid formulation of a vegf-antagonist
US20200171244A1 (en) 2017-05-24 2020-06-04 Sio2 Medical Products, Inc. Sterilizable pharmaceutical package for ophthalmic formulations
TW201904610A (zh) 2017-06-14 2019-02-01 德商拜耳製藥公司 用於治療新生血管型青光眼之非抗體vegf拮抗劑
WO2019020777A1 (en) 2017-07-26 2019-01-31 Formycon Ag LIQUID FORMULATION OF A VEGF ANTAGONIST
MY199833A (en) 2017-08-17 2023-11-24 Just Evotec Biologics Inc Method of purifying glycosylated protein from host cell galectins and other contaminants
MY202872A (en) * 2017-11-20 2024-05-28 Just Evotec Biologics Inc Aflibercept formulations containing a lysine salt as tonicifying agent and uses thereof
US11766489B2 (en) 2017-11-27 2023-09-26 4D Molecular Therapeutics, Inc. Adeno-associated virus variant capsids and use for inhibiting angiogenesis
KR20200093621A (ko) 2017-11-30 2020-08-05 리제너론 파아마슈티컬스, 인크. 혈관형성 눈 장애를 치료하기 위한 vegf 길항제의 용도
CN117405806A (zh) * 2017-12-13 2024-01-16 里珍纳龙药品有限公司 管理层析柱床支架的装置和系统及相关方法
EP3730126B1 (en) 2017-12-22 2025-05-14 Samsung Bioepis Co., Ltd. Liquid composition comprising vegf antagonist
US11524053B2 (en) * 2018-01-26 2022-12-13 The Regents Of The University Of California Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
RS67656B1 (sr) 2018-05-10 2026-02-27 Regeneron Pharma Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora
TW202016125A (zh) * 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
US11519020B2 (en) 2018-05-25 2022-12-06 Regeneron Pharmaceuticals, Inc. Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF
CN111378044B (zh) 2018-12-28 2022-07-15 长春金赛药业有限责任公司 抗体融合蛋白、制备方法及其应用
US20220204920A1 (en) 2019-05-16 2022-06-30 Formycon Ag Method for reducing methionine oxidation in recombinant proteins
US12059555B2 (en) 2019-09-03 2024-08-13 Amgen Inc. Injection device for drug delivery and packaging for the injection device
MX2022002980A (es) 2019-09-16 2022-04-06 Amgen Inc Metodo para la esterilizacion externa de un dispositivo de suministro de farmacos.
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN114867487A (zh) 2019-11-25 2022-08-05 加利福尼亚大学董事会 用于眼内新生血管的长效vegf抑制剂
IL309560B2 (en) 2019-12-06 2025-05-01 Regeneron Pharma Anti-VEGF protein preparations and methods for their production
MX2022006751A (es) 2019-12-06 2022-08-19 Regeneron Pharma Minitrampas de vegf y metodos de uso de las mismas.
CA3167020A1 (en) 2020-02-24 2021-09-02 Amgen Inc. Containers and systems for use during external sterilization of drug delivery devices
MX2022013812A (es) 2020-05-08 2022-12-15 Regeneron Pharma Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer.
EP4329734A4 (en) 2021-04-26 2025-04-02 Celanese EVA Performance Polymers LLC Implantable device for the delayed release of a macromolecular drug compound
FI4185318T3 (fi) 2021-05-17 2025-10-13 Regeneron Pharma Pitkäaikaisia, suuren annoksen VEGF-antagonistihoitoja angiogeenisten silmäsairauksien hoitoon
EP4145456A1 (en) 2021-09-06 2023-03-08 Bayer AG Prediction of a change related to a macular fluid
US20250002557A1 (en) 2021-11-24 2025-01-02 Suzhou Light Ferry Biomed. Co., Ltd Multi-specific ligand-binding molecules and applications thereof
WO2024029876A1 (ko) * 2022-08-02 2024-02-08 주식회사 파노로스바이오사이언스 변형된 융합 단백질 및 이의 용도
EP4588469A4 (en) 2022-09-16 2026-03-04 Qilu Pharmaceutical Co Ltd STABLE, HIGH-CONCENTRATION, SPONTANEOUSLY BUFFERING PHARMACEUTICAL COMPOSITION
AU2024322540A1 (en) * 2023-08-04 2026-03-05 Panolos Bioscience, Inc. Conjugate of modified fusion protein and scfv, and use thereof
WO2025213011A1 (en) 2024-04-05 2025-10-09 Amgen Inc. Method of assessing stopper movement in a drug delivery device

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9506466D0 (en) * 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production

Also Published As

Publication number Publication date
EP1183353A1 (en) 2002-03-06
HRP20010908B1 (en) 2006-05-31
DK1544299T3 (da) 2009-03-23
HK1185798A1 (en) 2014-02-28
FR13C0028I1 (fr) 2013-06-14
PT1183353E (pt) 2005-06-30
PT1544299E (pt) 2009-03-18
YU86901A (sh) 2004-05-12
CN101433715B (zh) 2013-04-17
ATE417928T1 (de) 2009-01-15
CA2376379C (en) 2007-08-07
CZ303656B6 (cs) 2013-01-30
HU230159B1 (hu) 2015-09-28
HUS1300052I1 (hu) 2016-08-29
ME00024B (me) 2010-02-10
NO20016036L (no) 2002-02-08
UA74146C2 (uk) 2005-11-15
DE60041159D1 (de) 2009-01-29
HRP20010908A2 (en) 2005-04-30
HUP0201515A3 (en) 2004-12-28
CN100523187C (zh) 2009-08-05
WO2000075319A1 (en) 2000-12-14
SK17522001A3 (sk) 2003-04-01
MEP3208A (xx) 2010-02-10
HUP0201515A2 (en) 2002-08-28
RU2265661C2 (ru) 2005-12-10
CN103349781B (zh) 2015-04-01
PL208247B1 (pl) 2011-04-29
FR13C0028I2 (fr) 2014-05-16
NZ515913A (en) 2004-01-30
CZ302689B6 (cs) 2011-09-07
NO2013010I1 (no) 2013-06-17
CY1108883T1 (el) 2014-07-02
ES2319305T3 (es) 2009-05-06
LTC1183353I2 (lt) 2023-02-27
EP1544299B1 (en) 2008-12-17
HK1043388A1 (en) 2002-09-13
JP4723140B2 (ja) 2011-07-13
ES2237429T3 (es) 2005-08-01
AU5040400A (en) 2000-12-28
DK1183353T3 (da) 2005-08-08
DE60019415T2 (de) 2006-03-09
ZA200110068B (en) 2002-12-06
RS50073B (sr) 2009-01-22
JP5273746B2 (ja) 2013-08-28
DE60019415D1 (de) 2005-05-19
AU2005201365B2 (en) 2007-08-09
MXPA01012630A (es) 2002-07-22
BE2013C029I2 (enExample) 2019-03-06
NO330775B1 (no) 2011-07-11
IL146890A (en) 2008-07-08
LTPA2013009I1 (lt) 2013-06-25
NO20016036D0 (no) 2001-12-10
CN1369009A (zh) 2002-09-11
LU92195I2 (fr) 2013-07-15
BR0011407A (pt) 2002-04-02
HK1132653A1 (en) 2010-03-05
AU779303B2 (en) 2005-01-13
CZ20014387A3 (cs) 2002-10-16
JP2003501089A (ja) 2003-01-14
NO20100656L (no) 2002-02-08
KR20020019070A (ko) 2002-03-09
CA2376379A1 (en) 2000-12-14
NO2013010I2 (no) 2013-05-15
CN103349781A (zh) 2013-10-16
IL146890A0 (en) 2002-08-14
CY2013019I2 (el) 2015-11-04
EP1183353B1 (en) 2005-04-13
CN101433715A (zh) 2009-05-20
BRPI0011407B1 (pt) 2018-09-25
HU229156B1 (en) 2013-09-30
EP1544299A1 (en) 2005-06-22
IL190234A0 (en) 2008-11-03
SK287332B6 (sk) 2010-07-07
CY2013019I1 (el) 2015-11-04
JP2011024595A (ja) 2011-02-10
PL352246A1 (en) 2003-08-11
KR100659477B1 (ko) 2006-12-20
BRPI0011407B8 (pt) 2021-05-25
NO2022060I1 (no) 2022-12-21
AU2005201365A1 (en) 2005-04-28
NO332559B1 (no) 2012-10-29

Similar Documents

Publication Publication Date Title
DE60019415D1 (de) Modifizierte chimärische polypeptide mit verbesserten pharmakokynetischen eigenschaften
MXPA02001911A (es) Anticuerpos ctla-4 humanos y sus usos.
EA200400518A1 (ru) Способы лечения глазных неоваскулярных заболеваний
ATE542137T1 (de) Immunocytokine mit modulierter selektivität
TR199902818T2 (xx) Be�eri kullan�m i�in antikorlar ve be�eri kullan�m i�in antikorlar olu�turmak i�in y�ntemler.
WO2002069900A3 (en) Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors
ATE406384T1 (de) Glp-1 fusion proteine
NO20025949D0 (no) Glukagonliknende peptid-1 analoger
DK1181319T3 (da) Kimære DR4-antistoffer og anvendelser deraf
WO2002024234A3 (en) Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
GEP20043349B (en) Methods of Controlling Cutworm Pests
ATE295423T1 (de) Phosphodiesterase 8
PT1343782E (pt) Pirimidinoaminas como moduladores de angiogénese
AU4128901A (en) Colored visco-elastic composition
DK2407536T3 (da) Adp-ribosyltransferase-fusionsvariantproteiner
DE50212628D1 (de) Verwendung wässriger Aufhellpräparationen zum Aufhellen von natürlichen und synthetischen Materialien
DE60130798D1 (de) "alpha1-untereinheit des natriumkanals, polypeptide davon und deren verwendung zur behandlung von generalisierter epilepsie mit fieberanfällen plus "
ATE319819T1 (de) Humane hirn-spezifische carboxypeptidase b
ATE404199T1 (de) Verwendung von naloxon zur behandlung von essstörungen
ATE240326T1 (de) Pyrrolo-(3,2-b)pyridine und ihre verwendung als 5-ht1f agonisten
ATE416782T1 (de) Medizinische verwendung von il-174 agonisten und antagonisten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1183353

Country of ref document: EP